Crossmark

Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression

Crossref DOI link: https://doi.org/10.1136/annrheumdis-2016-209424

Published Print: 2017-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ross, E A

Naylor, A J

O'Neil, J D

Crowley, T

Ridley, M L

Crowe, J

Smallie, T

Tang, T J

Turner, J D

Norling, L V

Dominguez, S

Perlman, H

Verrills, N M

Kollias, G

Vitek, M P

Filer, A

Buckley, C D

Dean, J L

Clark, A R
Funding

Funding for this research was provided by:

Medical Research Council (G0800207)

Arthritis Research UK (19614)

Arthritis Research UK (20298)
License Information

Text and Data Mining valid from 2017-03-01

Text and Data Mining valid from 2017-03-01

Version of Record valid from 2016-09-05
More Information

This article is maintained by: Elsevier

Article Title: Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression

Journal Title: Annals of the Rheumatic Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2016-209424

Content Type: article

Copyright: Copyright © 2016 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.